The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Neuro-degenerative receptor binding drug compositions. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Neuro-degenerative receptor binding drug compositions is a key innovation area in biosimilars

The neuro-degenerative receptor binding drugs bind to and modulate the action of various receptors that are associated with neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Glucagon-like peptide 1 (GLP-1) receptor agonists, brain derived neurotrophic factor (BDNF) receptor agonists, and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are the novel neuro-degenerative receptor binding drugs under development.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 150+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of neuro-degenerative receptor binding drug compositions.

Key players in neuro-degenerative receptor binding drug compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to neuro-degenerative receptor binding drug compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Biogen 340 Unlock Company Profile
AC Immune 309 Unlock Company Profile
F. Hoffmann-La Roche 293 Unlock Company Profile
AbbVie 279 Unlock Company Profile
Prothena 180 Unlock Company Profile
Lundbeck Foundation 168 Unlock Company Profile
BioArctic 146 Unlock Company Profile
Axon Neuroscience 124 Unlock Company Profile
TauRx Pharmaceuticals 99 Unlock Company Profile
Johnson & Johnson 87 Unlock Company Profile
Neurimmune Holding 81 Unlock Company Profile
Abbott Laboratories 80 Unlock Company Profile
Bristol-Myers Squibb 77 Unlock Company Profile
Eli Lilly and 72 Unlock Company Profile
UCB 67 Unlock Company Profile
Forschungszentrum Julich 67 Unlock Company Profile
Vivoryon Therapeutics 67 Unlock Company Profile
Proteome Sciences 64 Unlock Company Profile
Eisai 54 Unlock Company Profile
OncoTherapy Science 54 Unlock Company Profile
C2N Diagnostics 51 Unlock Company Profile
Takeda Pharmaceutical 47 Unlock Company Profile
AFFiRiS 45 Unlock Company Profile
PTC Therapeutics 43 Unlock Company Profile
Pfizer 40 Unlock Company Profile
Centre National de la Recherche Scientifique 37 Unlock Company Profile
AstraZeneca 36 Unlock Company Profile
Max-Planck-Gesellschaft 36 Unlock Company Profile
Cedars-Sinai Health System 36 Unlock Company Profile
Acorda Therapeutics 34 Unlock Company Profile
ProMIS Neurosciences 33 Unlock Company Profile
Sage Therapeutics 32 Unlock Company Profile
Tao Health Life Pharma 32 Unlock Company Profile
Perrigo 30 Unlock Company Profile
Ionis Pharmaceuticals 28 Unlock Company Profile
Nestle 28 Unlock Company Profile
Merck & Co 28 Unlock Company Profile
CommonSpirit Health 25 Unlock Company Profile
Grifols 24 Unlock Company Profile
Banyan Biomarkers 22 Unlock Company Profile
Massachusetts General Hospital 21 Unlock Company Profile
Immungenetics 21 Unlock Company Profile
GeNeuro 20 Unlock Company Profile
German Cancer Research Center 20 Unlock Company Profile
MorphoSys 20 Unlock Company Profile
National Research Council of Canada 20 Unlock Company Profile
Meiji Holdings 19 Unlock Company Profile
Annexon 19 Unlock Company Profile
General Hospital 19 Unlock Company Profile
OPKO Health 19 Unlock Company Profile

Source: GlobalData Patent Analytics

Biogen is the leading patent filer in neuro-degenerative receptor binding drug compositions and has more than 15 neurodegenerative drugs in development. It has recently received new drug approval from the US FDA for an anti-beta-amyloid monoclonal antibody (Aduhelm) for the treatment of AD. AC Immune and F. Hoffmann-La Roche are the other key patent filers in neuro-degenerative receptor binding drug compositions.

In terms of application diversity, PTC Therapeutics is the top company, followed by AFFiRiS and TauRx Pharmaceuticals. By means of geographic reach, Max-Planck-Gesellschaft holds the top position. MorphoSys and National Research Council of Canada stand in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.